Unichem Laboratories Limited AI Stock Analysis
Want to see IN:UNICHEMLAB full AI Analyst Report?
Unichem Laboratories Limited (UNICHEMLAB) AI Stock Analysis
Unichem Laboratories Limited
(NSE:UNICHEMLAB)
The overall score reflects improving fundamentals driven by stronger earnings and a solid, low-leverage balance sheet, offset by persistently weak and negative free cash flow, which is the main risk. Technicals indicate an intermediate uptrend but only neutral momentum and elevated volatility, keeping the near-term risk–reward balanced rather than strongly bullish. A reasonable earnings-based valuation provides support but not a significant margin of safety, resulting in a moderately attractive but not top-tier score.
Unichem Laboratories Limited (UNICHEMLAB) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 35.11B
- Dividend Yield
- ―
- Average Volume (3M)
- 9,485
- Price to Earnings (P/E)
- 10.4
- Beta (1Y)
- 1.17
- Revenue Growth
- 6.44%
- EPS Growth
- 283.10%
- Country
- India
- Employees
- 2,815
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Unichem Laboratories Limited Business Overview & Revenue Model
Company Description
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designe...
How the Company Makes Money
Unichem Laboratories makes money primarily by selling pharmaceutical products across a mix of business lines and geographies. Key revenue streams typically include: (1) Domestic formulations: revenue from marketing and distributing branded formulatio...
Unichem Laboratories Limited Financial Statement Overview
Summary
Revenue and net income have grown strongly with a clear turnaround from losses to double-digit net margins, and the balance sheet shows low leverage and rising equity, but persistently weak and volatile operating and free cash flow significantly dampen overall financial strength.
Income Statement
72PositiveBalance Sheet
82Very PositiveCash Flow
38Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.69B | 22.02B | 21.11B | 16.57B | 13.25B | 12.56B |
| Gross Profit | 9.18B | 6.60B | 12.47B | 3.17B | 7.92B | 8.07B |
| EBITDA | 5.35B | 4.49B | 2.65B | 742.36M | -456.07M | 803.28M |
| Net Income | 3.39B | 2.53B | 1.38B | -704.74M | -2.02B | 330.62M |
Balance Sheet | ||||||
| Total Assets | 39.08B | 37.37B | 35.69B | 31.69B | 31.93B | 33.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.60B | 2.99B | 895.80M | 1.52B | 1.89B | 3.73B |
| Total Debt | 4.98B | 5.00B | 4.60B | 2.48B | 3.14B | 3.49B |
| Total Liabilities | 11.26B | 10.20B | 11.19B | 8.07B | 7.58B | 7.00B |
| Stockholders Equity | 27.81B | 27.17B | 24.51B | 23.62B | 24.35B | 26.18B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.39B | -1.44B | -58.53M | -1.29B | -3.87B |
| Operating Cash Flow | 0 | -156.90M | -70.20M | 166.94M | -850.91M | -2.60B |
| Investing Cash Flow | 0 | 1.86B | -2.41B | 504.04M | 2.03B | 1.00B |
| Financing Cash Flow | 0 | 267.90M | 1.84B | -1.06B | -813.00M | 1.91B |
Unichem Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Negative. The current price of 498.05 is above the 20-day moving average (MA) of 497.37, below the 50-day MA of 524.48, and above the 200-day MA of 444.16, indicating a neutral trend. The MACD of -6.03 indicates Negative momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 31.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:UNICHEMLAB.
Unichem Laboratories Limited Peers Comparison
Overall Rating
IN:UNICHEMLAB68Neutral
IN:WINDLAS66Neutral
IN:HIKAL61Neutral
IN:GUFICBIO58Neutral
IN:MOREPENLAB57Neutral
IN:INDOCO48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | INR 35.07B | 10.36 | ― | ― | 6.44% | 283.10% | |
| 66Neutral | INR 20.72B | 31.24 | ― | 0.63% | 18.48% | -0.41% | |
| 61Neutral | INR 27.45B | -556.17 | ― | 0.27% | 8.93% | -149.51% | |
| 58Neutral | INR 47.29B | 64.62 | ― | 0.02% | 16.70% | 18.73% | |
| 57Neutral | INR 54.66B | 29.05 | ― | 0.20% | 30.20% | 91.17% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 48Neutral | INR 21.08B | 67.25 | ― | 0.09% | 10.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:UNICHEMLAB | Unichem Laboratories Limited | 498.05 | 21.60 | 4.53% | |
| IN:GUFICBIO | Gufic Biosciences Limited | 471.55 | 156.83 | 49.83% | |
| IN:HIKAL | Hikal Limited | 222.60 | -10.59 | -4.54% | |
| IN:INDOCO | Indoco Remedies Limited | 228.30 | -32.27 | -12.39% | |
| IN:MOREPENLAB | Morepen Laboratories Limited | 99.75 | 53.60 | 116.13% | |
| IN:WINDLAS | Windlas Biotech Ltd. | 1004.05 | 182.06 | 22.15% |
Unichem Laboratories Limited Corporate Events
Exchange Seeks Clarification as Unichem Labs Shares See Volume Surge
A significant spike in trading volume has been recorded in the shares of Unichem Laboratories Limited, prompting closer attention from the stock exchange. The move signals heightened investor activity and possibly shifting sentiment toward the pharma...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 10, 2026
